Weight loss results vary significantly by specific medication and dose: Semaglutide 2.4 mg (Wegovy): Clinical trials (STEP program) showed average weight reductions of 1517% at 68 weeks Tirzepatide (Zepbound): SURMOUNT trials demonstrated weight reductions of 1522% at 72 weeks, with results varying between populations with and without diabetes Liraglutide 3 mg (Saxenda): Typically produces 510% weight loss over 56 weeks The rate of weight loss is not linear
Tom comes in and we look at him like, Oh, my gosh, you have a theater background, so for us the most important thing is we show whats unique about him
The medication itselfsemaglutide or tirzepatidecan cause a mild burning or stinging sensation as it enters subcutaneous tissue
We can create custom combinations within the $99-$200 monthly range depending on which peptides you're using
Potential explanations include differences in the type of patients included, adherence to study treatment, sample size, duration of drug exposure, and GLP1 receptor activation with greater HbA1c reduction with longer-acting human GLP1-based analogs than with some short-acting exendin-4 analogs
